Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
Clinical trial NCT03945773 · COMPLETED
Trial details
- NCT number
- NCT03945773
- Sponsor
- Ipsen
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-08
- Primary completion
- 2023-05-11
- Enrollment
- 127
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.